The Cost-effectiveness and Cost-utility Analysis of the Use of Enoxaparin Compared with Heparin for Venous Thromboembolism Prophylaxis in Medical Inpatients in Iran

Purpose: The present study aims to evaluate the cost-effectiveness and cost-utility of using Enoxaparin compared to Heparin in Venous Thromboembolism (VTE) prophylaxis in medical inpatients, from payer’s perspective in Iran. Methods: To evaluate cost-effectiveness and cost-utility of the compared interventions, decision tree modeling technique was used. The main considered outcomes were Quality-Adjusted Life Years (QALY) for Cost-Utility Analysis (CUA) and Life Years Gained (LYG) for Cost-Effectiveness Analysis (CEA). Costs and consequences were evaluated for a three-month period and reported as Incremental Cost-Effectiveness Ratios (ICERs). One-way and Probabilistic Sensitivity Analysis (PSA) were conducted to evaluate the robustness of the model due to uncertainty in the input data. Results: Baseline ICERs were 60,376 USD/QALY and 71,077 USD/LYG per patient (with public tariff). The results of the sensitivity analysis showed the robustness of the model. Conclusion: As the estimated ICER per QALY is more than three times the reported Gross Domestic Product (GDP) per capita by world bank for Iran in 2017 ($5415), the use of Enoxaparin for VTE prophylaxis in medical inpatients doesn t seem to be a cost-effective intervention compared to the use of Heparin in Iran

کلیدواژه ها:

Cost-effectiveness ، Cost-utility ، Enoxaparin ، Heparin ، Venous thromboembolism ،